The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F21%3A00074228" target="_blank" >RIV/65269705:_____/21:00074228 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/21:00120783

Výsledek na webu

<a href="https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1718518" target="_blank" >https://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0040-1718518</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1055/s-0040-1718518" target="_blank" >10.1055/s-0040-1718518</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

Popis výsledku v původním jazyce

The objective of this study was to estimate the direct cost before and after diagnosis assessment in patients with Dravet&apos;s syndrome (DS). The basis of the economic study was to calculate the costs of health care before and after diagnosis of DS. We retrospectively evaluated all SCN1A positive patients with phenotype of DS treated in our hospital. Statistical analyses were performed by IBM SPSS Statistics 24.0 software. After the diagnosis of DS, there was a significant decline of health care costs (-85.6%) an average of Euro29.4 +/- 26.1 monthly per patient. We estimated the monthly costs at Euro204.5 +/- 167 (median: Euro193.9, range: Euro35.5-534.4) per patient before DS diagnosis. The major cost was for hospitalization in neurological department: Euro43.3 +/- 52 (median: Euro21.9, range: Euro9.5-179.4) per patient. Minimal cost per patient per months before DS diagnosis was cost of psychological testing/care and complementary rehabilitation (0.13 and 0.6% of total cost). After DS diagnosis, the major cost was focused on nonhospitalization care of patients (64.8%), minimal (Euro0) for genetic testing and major for outpatient care (18%, mean: Euro5.3, median: Euro7). DS results in essential health care utilization and high financial burden before diagnosis elucidation caused by repeated hospitalization and extensive diagnostics tests of &quot;epileptic encephalopathy of unknown etiology.&quot; The results of this study point out that early assessment of the diagnosis leads to significant decrease of the financial costs because of adequate therapeutic management and exclusion of redundant diagnostic testing after elucidation of correct diagnosis.

Název v anglickém jazyce

The Direct Costs of Dravet's Syndrome before and after Diagnosis Assessment

Popis výsledku anglicky

The objective of this study was to estimate the direct cost before and after diagnosis assessment in patients with Dravet&apos;s syndrome (DS). The basis of the economic study was to calculate the costs of health care before and after diagnosis of DS. We retrospectively evaluated all SCN1A positive patients with phenotype of DS treated in our hospital. Statistical analyses were performed by IBM SPSS Statistics 24.0 software. After the diagnosis of DS, there was a significant decline of health care costs (-85.6%) an average of Euro29.4 +/- 26.1 monthly per patient. We estimated the monthly costs at Euro204.5 +/- 167 (median: Euro193.9, range: Euro35.5-534.4) per patient before DS diagnosis. The major cost was for hospitalization in neurological department: Euro43.3 +/- 52 (median: Euro21.9, range: Euro9.5-179.4) per patient. Minimal cost per patient per months before DS diagnosis was cost of psychological testing/care and complementary rehabilitation (0.13 and 0.6% of total cost). After DS diagnosis, the major cost was focused on nonhospitalization care of patients (64.8%), minimal (Euro0) for genetic testing and major for outpatient care (18%, mean: Euro5.3, median: Euro7). DS results in essential health care utilization and high financial burden before diagnosis elucidation caused by repeated hospitalization and extensive diagnostics tests of &quot;epileptic encephalopathy of unknown etiology.&quot; The results of this study point out that early assessment of the diagnosis leads to significant decrease of the financial costs because of adequate therapeutic management and exclusion of redundant diagnostic testing after elucidation of correct diagnosis.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30210 - Clinical neurology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Neuropediatrics

ISSN

0174-304X

e-ISSN

—

Svazek periodika

52

Číslo periodika v rámci svazku

01

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

6

Strana od-do

6-11

Kód UT WoS článku

000578772900001

EID výsledku v databázi Scopus

2-s2.0-85094117132